Meeting News
Advertisement
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Advertisement
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Adding ruxolitinib before, during, and after HSCT to standard GVHD prophylaxis reduced the incidence of GVHD.
A retrospective study supported the safety of teclistamab and demonstrated a PFS benefit for patients with advanced myeloma.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
In a prospective study patients with Fanconi anemia were matched to healthy controls and underwent carotid artery ultrasound.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.